Compare ARK Genomic Revolution ETF (ARKG) vs D R Horton Inc (DHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs D R Horton Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while D R Horton Inc trades at $151.2 (market cap $42.98B). The key difference: D R Horton Inc pays a 1.19% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, D R Horton Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | DHI | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $184.04 |
52-Week Low | $23.09 | $129.82 |
Market Cap | — | $42.98B |
Enterprise Value | — | $47.70B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
D.R. Horton (DHI) trades at $151.58, up 1.36% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with declining revenue ($34.25B in 2025) and net income margins (9.51%), though valuation metrics remain reasonable (P/E 14.23). Analyst consensus leans neutral with a $163.13 price target, while cash flow trends show volatility with a $1.51B net outflow in 2025.
The housing market headwinds and cyclical nature of homebuilding present near-term risks, but DHI's scale and operational efficiency offer stability. With the stock trading below consensus targets and showing technical support at $145, value-oriented investors may find opportunity amid sector challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
